Vimarsana
Biggest News Aggregation in the World

Discovery Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Discovery Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Discovery Platform Today - Breaking & Trending Today

BBCNEWS World July 6, 2024 - Vimarsana News

BBCNEWS World July 6, 2024

— the annual rate at which prices have been going up. inflation peaked at more than 10% last year, forcing the bank to raise interest rates aggressively to try and bring it under control. but it has since fallen sharply. and on wednesday, official figures showed it was down to 3.9% in november, the lowest rate in 2 years, and far lower than expected. that's raised hopes the bank of england will be soon able to start cutting the cost of borrowing, easing pressure on businesses and households. here's our economics editor, faisal islam. arp and now sharply down. over the past year, in...

CNNW CNN July 6, 2024 - Vimarsana News

CNNW CNN July 6, 2024

planning to continue to rally on the campaign trail. >> this party is no longer the pro corporate party. that is a huge shift in america. >> senator feinstein, do you still feel like you're sit to serve? >> new health revelations coming to light, complications including encephalitis. >> we could be left with difficulties of memory. >> we all have health issues. she is performing, doing her job. >> did four children survive a deadly plane crash in the amazon jungle? the mystery and search is intensifying. >> the president's tweet was related and the information could not be confirmed....

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting - Vimarsana News

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy...

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - Vimarsana News

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in...

Candel Therapeutics : Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights - Form 8-K -March 28, 2024 at 07:48 am EDT - Vimarsana News

Candel Therapeutics : Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights - Form 8-K -March 28, 2024 at 07:48 am EDT

Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for...